CD274 and cancer: Since inhibition of the EMT/β-catenin/STT3/PD-L1 axis by etoposide downregulated PD-L1 expression in both CSC and non-CSC populations of mesenchymal-like cancer cells, we sought to determine whether etoposide would enhance the therapeutic efficacy of immune checkpoint blockade therapy.